This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Save the date!
November 6–8, 2023Munich, Germany



Virogin Biotech is a clinical-stage oncolytic virus company focused on novel engineering of the herpes simplex virus (HSV-1) to generate strong and durable anti-tumor immune response against solid tumors.  Our lead program, VG161, is an oncolytic HSV-1 designed to encode a novel combination of cytokines (IL12/IL15/IL15RA) and a PD-L1 blocking peptide that together induces a robust cytotoxic immune response and leads to systemic anti-tumor effects (product candidate currently in Phase 1/2 in China; Phase 2 US IND approved, first patient planned Q4 2022).  We are also developing an oncolytic HSV-1 that is uniquely engineered to enhance tumor-specific replication and payload expression via Transcription and Translation Dual Regulation (TTDR).  This next generation oncolytic virus, VG201, is highly potent and has shown to improve efficacy without compromising safety (planned Phase I in North America Q4 2022).  Due to the high payload capacity to include additional transgenes, we have developed a differentiated HSV-1 oncolytic virus platform with the ability to design multiple therapeutic products.  Virogin Biotech is also building a mRNA tumor vaccine platform as a strategy to prime the immune system in order to realize the full potential of oncolytic virotherapy.  With over $300M USD raised to date, we are well-funded to expand our pipeline and initiate multiple clinical programs. 

We're bringing you

  • Company Presentations